Standard BioTools S-4/A Sets Vote on Treeline Reverse Merger and $5.5M Mass Cytometry Sale
LAB is trading near its 52-week low of $0.618 (2.8% above the low) on light trading volume (0.4× avg).
Summary
Standard BioTools filed the final S-4 amendment for its all-stock reverse merger with Treeline Biosciences, setting the stockholder vote on share issuance, a 1-for-20 to 1-for-40 reverse split, and the $5.5 million mass cytometry sale to Element. Existing holders would keep about 16% of the combined company plus contingent value rights on legacy asset proceeds.
Key Events · M&A and Partnerships · LAB
-
Treeline Reverse Merger Goes to Vote
All-stock merger values Treeline at $2.5 billion and Standard BioTools at $460 million; former LAB holders would own about 16% of the combined company and Treeline holders about 84%.
-
Massive Dilution From Share Issuance
Up to 2,007,493,452 shares would be issued in the merger, about 70.7% of the 2.84 billion fully diluted shares shown pre-split, plus up to 76,000,000 CVR shares.
-
Reverse Split Needed for Nasdaq Listing
A 1-for-20 to 1-for-40 reverse split is proposed to lift the share price above Nasdaq's $4.00 initial listing threshold; the stock closed at $0.66 on October 13, 2026.
-
Element Mass Cytometry Sale Added to Ballot
The $5.5 million cash sale of the mass cytometry business to Element Biosystems requires majority-of-outstanding stockholder approval and is conditioned on the merger closing.
Analysis · LAB · Life Sciences
This proxy puts the all-stock reverse merger with Treeline Biosciences to a stockholder vote, and it is the event that determines whether LAB survives as a standalone company. Standard BioTools shareholders end up with roughly 16% of the combined company while Treeline holders get about 84%, so control passes to Treeline and the ticker becomes TRLN. The filing also adds a separate vote on selling the mass cytometry business to Element for $5.5 million, a condition tied to the merger closing. Existing holders receive one CVR per share tied to future proceeds from the legacy businesses, capped at 76 million shares, and that payout is not guaranteed. The reverse split of 1-for-20 to 1-for-40 is needed to clear Nasdaq's $4.00 initial listing price, against a stock now trading near $0.64. The vote is the binary event: approval closes the deal, rejection leaves a company the board itself has said may pursue liquidation.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 44.4% of the 293 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $250.2M. The 52-week trading range was $0.62 to $1.72. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.